8.25

3.62% -0.31

Anavex Life Sciences Corporation (AVXL)

Overview News Price History Option Chain Financials Why AVXL Down? Discussions Forecast Stock Split

Anavex Life Sciences Corporation stock is traded at $8.25, with a volume of 811.44K. It is down -3.62% in the last 24 hours and down -5.39% over the past month. Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Previous Close:

$8.56

Open:

$8.5

24h Volume:

811.44K

Relative Volume:

0.82

Market Cap:

$796.20M

Revenue:

Net Income/Loss:

$-43.16M

P/E Ratio:

-15.00

EPS:

-0.55

Net Cash Flow:

$-29.31M

1W Performance:

-11.86%

1M Performance:

-5.39%

6M Performance:

-10.71%

1Y Performance:

+112.63%

1-Day Range:

$8.23

$8.6779

1-Week Range:

$8.20

$9.48

52-Week Range:

$3.51

$14.44

Anavex Life Sciences Corporation Stock (AVXL) Company Profile

Name

Anavex Life Sciences Corporation

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

844-689-3939

Address

630 5TH AVENUE, NEW YORK

Employee

Twitter

@anavexlifesci

Next Earnings Date

2024-12-31

Latest SEC Filings

AVXL's Discussions on Twitter

Compare AVXL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVXL Anavex Life Sciences Corporation	8.25	796.20M	0	-43.16M	-29.31M	-0.55
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-23-22	Initiated	Berenberg	Buy
Sep-23-21	Initiated	BTIG Research	Buy
Dec-16-20	Reiterated	H.C. Wainwright	Buy
Sep-28-20	Initiated	Ladenburg Thalmann	Buy
Feb-27-20	Initiated	Cantor Fitzgerald	Overweight
Jun-18-19	Initiated	Janney	Buy
May-16-18	Resumed	Maxim Group	Buy
Mar-08-18	Initiated	ROTH Capital	Buy
Feb-13-18	Reiterated	Maxim Group	Buy
Sep-29-17	Resumed	Noble Financial	Buy
Feb-07-17	Initiated	Noble Financial	Buy
Mar-29-16	Initiated	FBR Capital	Outperform

View All

Anavex Life Sciences Corporation Stock (AVXL) Latest News

May 09, 2025

Anavex Life Sciences Corp expected to post a loss of 15 cents a shareEarnings Preview - TradingView

May 09, 2025

Is Anavex Life Sciences Corp. (AVXL) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey

May 09, 2025

May 06, 2025

Closing Bell Recap: Anavex Life Sciences Corporation (AVXL) Ends at 8.91, Reflecting a -4.81 Downturn - DWinneX

May 06, 2025

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Fina - GuruFocus

May 06, 2025

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 - The Manila Times

May 06, 2025

Anavex Life Sciences Corp. to Announce Second Fiscal Quarter Financial Results on May 13, 2025 - Nasdaq

May 06, 2025

Anavex Life Sciences Earnings Preview: Key Updates Coming on Alzheimer's and Rare Disease Programs - Stock Titan

May 06, 2025

May 04, 2025

Envestnet Asset Management Inc. Purchases 20,771 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

May 04, 2025

Head-To-Head Comparison: Anavex Life Sciences (NASDAQ:AVXL) vs. Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World

May 04, 2025

May 02, 2025

Taking on analysts’ expectations and winning: Anavex Life Sciences Corporation (AVXL) - Sete News

May 02, 2025

Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by JPMorgan Chase & Co. - Defense World

May 02, 2025

May 01, 2025

Anavex Life Sciences' Schizophrenia Clinical Study Completes Enrollment - marketscreener.com

May 01, 2025